Article type
Abstract
Background: The health-related quality of life (HRQoL) instruments normally applied to oral cavity cancer (OCC) and oropharyngeal cancer (OC) patients have been developed for head and neck cancer patients. The health-related quality of life (HRQoL) instruments commonly applied to oral cavity cancer OCC and OC patients have been developed for head and neck cancer patients. Unfortunately, information about their development process, metric properties, and administration issues is dispersed. Therefore, a comparative evaluation that identifies HRQoL instruments developed or validated for these patients would facilitate the choice of the most suitable for clinical or research purposes.
Objective: This study aimed to identify HRQoL instruments available for OCC and OC patients and summarize the evidence on the conceptual and measurement model, psychometric properties, interpretability, and administration issues.
Materials and methods: We conducted a systematic search in MEDLINE, EMBASE, LILACS, and CENTRAL until April 2023. Articles reporting information on concept model measurement, psychometric properties, and administration issues of instruments for measuring HRQoL in OCC or OC patients were included. Two researchers independently evaluated each instrument, applying the Evaluating Measures of Patient-Reported Outcomes (EMPRO) tool. The overall EMPRO score and seven attribute-specific scores were calculated (range 0–100, worst to best): Conceptual and Measurement model, Reliability, Validity, Responsiveness, Interpretability, Burden, and Alternative forms.
Results We identified 7 instruments evaluated in 42 articles. The overall score varied between 84.1 and 29.3, with only five questionnaires over the threshold score of 50.0. EORTC QLQ-H&N43 (head and cancer-specific questionnaire) achieved the highest score (84.1), followed by EORTC QLQ-C30 (HRQoL Neoplasms cancer-specific questionnaire) (80.0), EORTC QLQ-OH15 (oral health quality of life specific questionnaire) (73.7). In general terms, Conceptual and Measurement model and Interpretability showed the best performance, while Responsiveness showed the worst.
Conclusion EORTC QLQ-H&N43, EORTC QLQ-C30 and EORTC QLQ-OH15 are recommended for assessing HRQoL in patients with OCC or OC in cross-sectional and longitudinal studies. Our results will help clinicians and investigators to choose the best instrument for evaluating HRQoL in patients with OCC and OC.
Statement: In this study were not involved public and/or consumers
Objective: This study aimed to identify HRQoL instruments available for OCC and OC patients and summarize the evidence on the conceptual and measurement model, psychometric properties, interpretability, and administration issues.
Materials and methods: We conducted a systematic search in MEDLINE, EMBASE, LILACS, and CENTRAL until April 2023. Articles reporting information on concept model measurement, psychometric properties, and administration issues of instruments for measuring HRQoL in OCC or OC patients were included. Two researchers independently evaluated each instrument, applying the Evaluating Measures of Patient-Reported Outcomes (EMPRO) tool. The overall EMPRO score and seven attribute-specific scores were calculated (range 0–100, worst to best): Conceptual and Measurement model, Reliability, Validity, Responsiveness, Interpretability, Burden, and Alternative forms.
Results We identified 7 instruments evaluated in 42 articles. The overall score varied between 84.1 and 29.3, with only five questionnaires over the threshold score of 50.0. EORTC QLQ-H&N43 (head and cancer-specific questionnaire) achieved the highest score (84.1), followed by EORTC QLQ-C30 (HRQoL Neoplasms cancer-specific questionnaire) (80.0), EORTC QLQ-OH15 (oral health quality of life specific questionnaire) (73.7). In general terms, Conceptual and Measurement model and Interpretability showed the best performance, while Responsiveness showed the worst.
Conclusion EORTC QLQ-H&N43, EORTC QLQ-C30 and EORTC QLQ-OH15 are recommended for assessing HRQoL in patients with OCC or OC in cross-sectional and longitudinal studies. Our results will help clinicians and investigators to choose the best instrument for evaluating HRQoL in patients with OCC and OC.
Statement: In this study were not involved public and/or consumers